Ayala Pharmaceuticals (NASDAQ:AYLA) Upgraded to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a hold rating to a buy rating in a research report sent to investors on Tuesday, Zacks.com reports. Zacks Investment Research currently has $8.00 price target on the stock.

According to Zacks, “Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala Pharmaceuticals Inc. is based in Rehovot, Israel. “

Several other analysts also recently commented on AYLA. Maxim Group started coverage on shares of Ayala Pharmaceuticals in a research report on Monday, December 20th. They set a buy rating and a $22.00 price objective on the stock. Jefferies Financial Group upgraded shares of Ayala Pharmaceuticals from a hold rating to a buy rating and raised their price objective for the company from $12.00 to $17.00 in a research report on Tuesday, November 30th. HC Wainwright began coverage on shares of Ayala Pharmaceuticals in a research report on Monday, December 20th. They set a buy rating and a $18.00 price objective on the stock. Finally, TheStreet downgraded shares of Ayala Pharmaceuticals from a c- rating to a d+ rating in a report on Thursday, October 7th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and an average price target of $21.14.

Shares of AYLA stock opened at $6.63 on Tuesday. Ayala Pharmaceuticals has a 12-month low of $6.26 and a 12-month high of $28.68. The firm’s 50 day moving average is $9.20 and its 200 day moving average is $10.75.

Ayala Pharmaceuticals (NASDAQ:AYLA) last issued its earnings results on Monday, November 15th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.12. Ayala Pharmaceuticals had a negative net margin of 1,177.26% and a negative return on equity of 91.26%. The company had revenue of $0.63 million for the quarter, compared to analysts’ expectations of $0.82 million. As a group, equities analysts predict that Ayala Pharmaceuticals will post -2.7 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP boosted its stake in shares of Ayala Pharmaceuticals by 36.5% during the 3rd quarter. Wellington Management Group LLP now owns 961,609 shares of the company’s stock worth $10,905,000 after purchasing an additional 257,246 shares during the period. Marshall Wace North America L.P. purchased a new position in shares of Ayala Pharmaceuticals during the 2nd quarter worth about $502,000. Citadel Advisors LLC purchased a new position in shares of Ayala Pharmaceuticals during the 2nd quarter worth about $107,000. Finally, Morgan Stanley purchased a new position in shares of Ayala Pharmaceuticals during the 1st quarter worth about $46,000. 19.39% of the stock is owned by hedge funds and other institutional investors.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.

Featured Article: Investing strategies using the yield curve

Get a free copy of the Zacks research report on Ayala Pharmaceuticals (AYLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ayala Pharmaceuticals (NASDAQ:AYLA)

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.